Incidentally, kinase inhibitors such as target epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase, B‐Raf proto‐oncogene, and ROS proto‐oncogene 1 are specifically effective in NSCLC with mutations, but these are not recommended for patients who do not have these mutations.9 Here, EGFR is linked to non-small cell lung carcinoma.